Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
Affymetrix Launches New Custom Array Design Options
The NimbleExpress(TM) Array Program Provides Rapid, Cost-Efficient Solution for
Smaller Expression Studies
SANTA CLARA, Calif., June 21 /PRNewswire-FirstCall/ -- Affymetrix, Inc.
(NASDAQ:AFFX) today announced the launch of the NimbleExpress(TM) Array
Program, an extension to its line of custom microarrays, to provide researchers
with a flexible, cost-effective method of designing customized expression
arrays for smaller scale studies or pilot experiments.
(For an interactive version of this press release with additional information,
please go to http://www.affymetrix.com/pr and click on the release title.)
The NimbleExpress Array Program extends Affymetrix' current Custom Expression
Array Program (CustomExpress(TM)) and broadens the company's range of custom
solutions. NimbleExpress arrays offer the same level of performance and service
as the existing Affymetrix CustomExpress offering, but require nominal upfront
fees and have a minimum order size of just ten arrays.
Affymetrix continues to offer the most comprehensive line of custom microarray
expression products, with complete flexibility in terms of microarray content
and order size. Affymetrix custom array programs enable customers to create
microarrays with flexible format options to measure from 520 to 61,000
transcripts on a single array.
NimbleExpress arrays use Affymetrix' proven strategy of multiple pairs of
perfect match and mismatch oligos per transcript for the best balance of
sensitivity and specificity. The new NimbleExpress arrays are useful to study
expression of up to 12,000 transcripts (282,000 unique oligos) on a single
array. Affymetrix will offer a four-week turnaround time for the NimbleExpress
custom arrays, providing researchers with rapid delivery of cost-efficient,
custom microarray tools for gene expression, genome tiling, and other
experiments.
"The NimbleExpress arrays are complementary to our existing catalog arrays and
CustomExpress(TM) Program," said Lianne McLean, Director, Gene Expression
Marketing, Affymetrix. "These arrays deliver on a smaller scale, the same high
quality performance, service, and support that customers have come to expect
from Affymetrix GeneChip(R) CustomExpress(TM) program. NimbleExpress arrays
provide an easy way for scientists making their own arrays to cost-effectively
pilot new design strategies with the full benefits of the GeneChip(R) System,
including photolithographic manufacturing and our proven probe set strategy."
NimbleExpress arrays will be manufactured by NimbleGen Systems Inc. for
Affymetrix, using photolithographic Maskless Array Synthesis (MAS) technology.
NimbleExpress Arrays are compatible with the latest generation GeneChip System,
which includes new instruments, reagents, and high-performance analysis
algorithms. All NimbleExpress microarrays are individually produced and quality
tested, to ensure that they meet Affymetrix' high standards for quality and
reproducibility.
For more information about NimbleExpress arrays, please visit
http://www.affymetrix.com/.
About Affymetrix:
Affymetrix is a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor technology to
the life sciences, Affymetrix develops and commercializes systems that enable
scientists to improve the quality of life. The Company's customers include
pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit research
institutes. Affymetrix offers an expanding portfolio of integrated products and
services, including its integrated GeneChip brand platform, to address growing
markets focused on understanding the relationship between genes and human
health. Additional information on Affymetrix can be found at
http://www.affymetrix.com/.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including,
but not limited to risks of the Company's ability to achieve and sustain higher
levels of revenue, higher gross margins, reduced operating expenses,
uncertainties relating to technological approaches, manufacturing, product
development, market acceptance (including uncertainties relating to product
development, use and market acceptance of the GeneChip(R) CustomExpress(TM)
Arrays and NimbleExpress(TM) Arrays), personnel retention, uncertainties
related to cost and pricing of Affymetrix products, dependence on collaborative
partners, uncertainties relating to sole source suppliers, uncertainties
relating to FDA and other regulatory approvals, competition, risks relating to
intellectual property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in Affymetrix' Form 10-K
for the year ended December 31, 2003 and other SEC reports, including its
Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix' expectations with regard thereto or any
change in events, conditions, or circumstances on which any such statements are
based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks
owned or used by Affymetrix, Inc.
DATASOURCE: Affymetrix, Inc.
CONTACT: Wes Conard, Associate Director, Public Relations,
+1-408-731-5791, or investor contact, Doug Farrell, Vice President, Investor
Relations, +1-408-731-5285, both of Affymetrix, Inc.
Web site: http://www.affymetrix.com/